Diaceutics (DXRX) Stock Overview
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DXRX from our risk checks.
DXRX Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Diaceutics PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.60 |
| 52 Week High | UK£1.80 |
| 52 Week Low | UK£1.25 |
| Beta | 0.88 |
| 1 Month Change | 10.34% |
| 3 Month Change | 9.59% |
| 1 Year Change | 10.73% |
| 3 Year Change | 51.66% |
| 5 Year Change | 44.80% |
| Change since IPO | 67.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| DXRX | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 3.2% | -0.04% | -1.8% |
| 1Y | 10.7% | -3.6% | 16.0% |
Return vs Industry: DXRX exceeded the UK Life Sciences industry which returned -3.6% over the past year.
Return vs Market: DXRX underperformed the UK Market which returned 16% over the past year.
Price Volatility
| DXRX volatility | |
|---|---|
| DXRX Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DXRX has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: DXRX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 205 | Ryan Keeling | www.diaceutics.com |
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic event, enabling teams to act while treatment decisions are still pending; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports.
Diaceutics PLC Fundamentals Summary
| DXRX fundamental statistics | |
|---|---|
| Market cap | UK£135.81m |
| Earnings (TTM) | UK£97.00k |
| Revenue (TTM) | UK£38.44m |
Is DXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXRX income statement (TTM) | |
|---|---|
| Revenue | UK£38.44m |
| Cost of Revenue | UK£6.96m |
| Gross Profit | UK£31.48m |
| Other Expenses | UK£31.38m |
| Earnings | UK£97.00k |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 22, 2026
| Earnings per share (EPS) | 0.0011 |
| Gross Margin | 81.90% |
| Net Profit Margin | 0.25% |
| Debt/Equity Ratio | 0% |
How did DXRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 23:01 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diaceutics PLC is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hayley Palmer | Canaccord Genuity |
| Julie Simmonds | Panmure Liberum |
| Natalia Webster | RBC Capital Markets |